Hepatoma cells were treated with an RTK inhibitor (Sorafenib) or a monoclonal anti-VEGF antibody (Avastin), both in vitro and in vivo, at doses employed in clinical trials. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.